{"id":617292,"date":"2024-06-18T20:11:06","date_gmt":"2024-06-19T00:11:06","guid":{"rendered":"https:\/\/platohealth.ai\/cirms-31-million-boost-for-cancer-and-eye-disease-research\/"},"modified":"2024-06-19T08:33:10","modified_gmt":"2024-06-19T12:33:10","slug":"cirms-31-million-boost-for-cancer-and-eye-disease-research","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/cirms-31-million-boost-for-cancer-and-eye-disease-research\/","title":{"rendered":"CIRM\u2019s $31 million boost for cancer and eye disease research","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/a><\/figure>\n

The California Institute for Regenerative Medicine (CIRM)<\/a> recently approved nearly $31 million in funding, further cementing our commitment to advancing the field of regenerative medicine. This substantial investment aims to drive clinical research targeting various cancers and eye diseases. <\/p>\n

CIRM\u2019s dedication to fostering innovative treatments is demonstrated through its clinical program, which funds eligible stem cell and gene therapy-based projects at all stages of clinical trial development. With these new awards, CIRM\u2019s clinical portfolio now includes 106 clinical trials. <\/p>\n

During CIRM\u2019s April Application Review Subcommittee (ARS) meeting, the following vital projects were approved for funding: <\/p>\n

\n\n\n\n\n\n\n
Application<\/strong>\u202f \u202f <\/td>\nProgram Title<\/strong>\u202f \u202f <\/td>\nPrincipal Investigator\/Institution<\/strong>\u202f <\/td>\nAmount<\/strong>\u202f \u202f <\/td>\n<\/tr>\n
CLIN2-15282\u202f <\/td>\nRPESC-RPE Therapy for dry Age-related Macular Degeneration\u202f \u202f <\/td>\nStern, Jeffrey H \u2013 Luxa Biotechnology\u202f <\/td>\n$4,009,675\u202f <\/td>\n<\/tr>\n
CLIN2-15311\u202f <\/td>\nA Phase I\/IIa Study to Evaluate the Efficacy of a Gene Therapy with Standard of Care Therapy in Newly Diagnosed High Grade Glioma\u202f \u202f <\/td>\nKasahara, Noriyuki \u2013 UCSF\u202f <\/td>\n$11,807,220\u202f <\/td>\n<\/tr>\n
CLIN2-15343\u202f <\/td>\nA Phase 1B Study Evaluating the Safety and Efficacy of an Allogenic Cell Therapy in Subjects with Clear Cell Renal Cell Carcinoma (ccRCC)\u202f <\/td>\nLe Gall, John \u2013 Allogene Therapeutics\u202f <\/td>\n$15,000,000\u202f <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

 
These projects are poised to make significant strides in developing new therapies that could revolutionize the treatment landscape for cancer and eye diseases. By supporting these cutting-edge research initiatives, CIRM continues to pave the way for breakthroughs in regenerative medicine. <\/p>\n

Stay tuned for updates on the progress of these exciting projects and learn how they are making a difference in healthcare by signing up for our monthly newsletter<\/a>. <\/p>\n